Leronlimab sits at the nexus of exceptionally important biological regulatory processes involving inflammatory and immune-mediated functions. It really should be re-named MiracleMolecule but Respert probably has the patent on that already.

It is painful from a humanitarian standpoint to witness a drug with this much potential to move the needle clinically remain sidelined. BP has under its wings a vast array of clinical scientists, they are not all lobbyists or salespeople, and it is inevitable that the science gets someone’s attention; very likely it already has and we are just not privy to the details. At some point SeaBisquit is released from the gate and the race against War Admiral will be underway. I have punched my exacta ticket and SeaBisquit will be commanding a princely stud fee in due course.

We need our horse on the track, not in the barn…maybe I should print up new Cytodyn letterhead with that memo header and send it to headquarters in Vancouver.